Which two MDR-TB drugs require monitoring of the QT interval during therapy?

Bedaquiline and Delamanid.

QT interval prolongation is a key safety concern with certain MDR-TB drugs, so monitoring the heart's electrical activity with ECGs during therapy helps detect dangerous changes early. Bedaquiline and delamanid are both known to prolong the QT interval, so baseline and periodic QTc assessments are recommended, along with checking electrolytes and avoiding other QT-prolonging drugs when possible. The other drugs listed do not carry the same primary risk of QT prolongation, and their safety monitoring focuses on different issues.

Bedaquiline and Isoniazid.

Delamanid and Rifampin.

Rifapentine and Ethambutol.

Want more questions?

All options are one-time payments.

$25.99

30 day pass for new members

All the basics to get you started

  • Ad-free experience
  • View your previous attempt history
  • Mobile app access
  • In-depth explanations
  • 30 day premium pass access
$59.99$171.99 usd

6 month DELUXE pass (most popular)

Full access FOR 6 MONTHS! & the ultimate digital PDF study guide (BONUS)

  • $171.99 usd value for $59.99! You save $106!
  • Ad-free experience
  • View your previous attempt history
  • Mobile app access
  • In-depth explanations
  • 6 months of full access
  • Ultimate digital PDF study guide included
  • Priority support
$15.99 $24.99

Ultimate digital PDF study guide

For those that prefer a more traditional form of learning

  • Available for instant download
  • Available offline
  • Hundreds of practice multiple choice questions
  • Comprehensive content
  • Detailed explanations
Image Description
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy